Method for the treatment of amyloidoses

• US 20110130549A1
• Filed: 02/27/2008
• Published: 06/02/2011
• Est. Priority Date: 02/27/2007
• Status: Active Grant

• Current Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated)
• Original Assignee: Abbott GmbH & Company KG (Abbott Laboratories)
• Inventors: Barghorn, Stefan, Hillen, Heinz, Gross, Gerhard, Krantz, Carsten, Grimm, Christiane, Draguhn, Andreas, Nimmrich, Volker, Ebert, Ulrich, Bruehl, Claus
• Granted Patent: US 8,895,004 B2
• Time in Patent Office: Days
• US Class Current: 530/389.8
• CPC Class Codes: A61K 31/015 carbocyclic
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00

Abstract

The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer'"'"'s disease in a subject in need thereof, characterized in that it comprises administering an inhibitor of the interaction between Aβ globulomer and the P/Q type voltage-gated presynaptic calcium channel to said subject.

Claims

1. The use of an inhibitor of the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel in the manufacture of a medicament for the treatment of an amyloidosis.

2. The use of claim 1, wherein the amyloidosis is Alzheimer'"'"'s disease.

3. The use of claim 1 or 2, wherein the inhibitor of the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel binds to the P/Q type voltage-gated presynaptic calcium channel.

4. The use of claim 3, wherein the inhibitor of the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel binds to the P/Q type voltage-gated presynaptic calcium channel with an affinity of K_D≦

1 μ

M.

5. The use of claim 1 or 2, wherein the inhibitor of the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel binds to Aβ

globulomer.

6. The use of claim 5, wherein the inhibitor of the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel specifically binds to Aβ

globulomer.

7. The use of any of claims 1 to 6, wherein the inhibitor reduces the interaction between Aβ

globulomer and the P/Q to less than one half of its normal value.

8. The use of any of claims 1 to 7, wherein the treatment is for the restoration of synaptic function.

9. The use of any of claims 1 to 8, wherein the treatment is for the restoration of long-term potentiation.

10. The use of any of claims 1 to 9, wherein the treatment is for the restoration of memory function.

11. The use of any of claims 1 to 10, wherein the treatment is for the restoration of performance of activities of daily living (ADL) capacity.

12. A method for identifying an inhibitor of the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel, comprising determining the inhibitory effect on the interaction between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel of said agent.

13. The method of claim 12, comprising determining the effect of said agent on a cell expressing at least the P/Q type voltage-gated presynaptic calcium channel and an intracellular calcium sensor.

14. The method of claim 12, comprising determining the physical contact between Aβ

globulomer and the P/Q type voltage-gated presynaptic calcium channel.